Longterm effects of COVID-19 on health and quality of life
COVIDOM: Longterm Morbidity of SARS-CoV-2 Infection and COVID-19 Disease - Consequences for Health Status and Quality of Life (NAPKON-POP)
This study is trying to see how COVID-19 affects people's health and quality of life in the long run after they've been infected with the virus.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital Schleswig-Holstein Academic / other |
| Locations | 3 sites (Würzburg, Bavaria and 2 other locations) |
| Trial ID | NCT04679584 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the longterm morbidity associated with SARS-CoV-2 infection and COVID-19 disease. It will involve a population-representative sample of individuals who have been infected with the virus, examining various organ systems to identify potential longterm health impacts. Participants will undergo detailed clinical and biochemical evaluations to understand the prevalence and consequences of these sequels on health status and quality of life. The study will also explore how behavioral changes due to the pandemic may affect overall well-being.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have had a PCR-confirmed SARS-CoV-2 infection and reside in the targeted geographic areas.
Not a fit: Patients currently experiencing acute SARS-CoV-2 infection or reinfection will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the longterm health effects of COVID-19, leading to better management and treatment strategies for affected individuals.
How similar studies have performed: Other studies have indicated potential longterm effects of COVID-19, but this study aims to provide a comprehensive population-level assessment, making it a significant contribution to the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * PCR-confirmed SARS-CoV-2 infection * living in one of the target areas * age at least 18 years * written informed consent Exclusion Criteria: * Acute SARS-CoV-2 infection or reinfection
Where this trial is running
Würzburg, Bavaria and 2 other locations
- University Hospital Wuerzburg — Würzburg, Bavaria, Germany (Not_yet_recruiting)
- University Hospital Schleswig-Holstein, Campus Kiel — Kiel, Schleswig-Holstein, Germany (Recruiting)
- University Hospital Charité Berlin — Berlin, Germany (Not_yet_recruiting)
Study contacts
- Study coordinator: Stefan Schreiber, Prof. Dr.
- Email: s.schreiber@mucosa.de
- Phone: 0049 (0)431 500 22201
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.